McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc. 2000; 48:1707 -1713 This is the first randomized study of postsurgical cancer patients to link a specialized home care intervention by advanced practice nurses with improved survival. Additional research is needed to test home care interventions aimed at maintaining quality of life outcomes and their effects on survival of these patients.
Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003; 21:2268 -2275 This study tested whether older patients were offered trials less often than younger patients and whether older patients who were offered trials were more likely to refuse participation than younger patients. In a multivariate analysis that included comorbid conditions, age and stage were the only predictors of whether a patient was offered a trial. The greatest impediment to enrolling older women onto trials in the setting of this study was the physicians' perceptions about age and tolerance of toxicity. Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients 70 years of age or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity. Advanced age alone should not preclude appropriate treatment for NSCLC. Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects.
Alibhai SM, Naglie G, Nam R, et al. Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol. 2003; 21: 3318-3327. This decision analysis study explores the treatment of localized prostate cancer with the goal of providing decision tables for individual cancer patients. Potentially curative therapy results in significantly improved life expectancy and quality-adjusted life expectancy for older men with few comorbidities and moderately or poorly differentiated localized prostate cancer. Age should not be a barrier to treatment in this group.
